Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 7/20 | 0.52 |
| ▸ | BRAF | P15056 | 3/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | WNT1 | P04628 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10160893 | 0.88 | MAPKAPK5 (0.51) | MAPKAPK5BRAFPIK3CDSYKGSK3B | |
| SCHEMBL10160851 | 0.86 | MAPKAPK5 (0.52) | MAPKAPK5BRAFPIK3CDSYKGSK3B | |
| SCHEMBL10160823 | 0.84 | MAPKAPK5 (0.50) | MAPKAPK5BRAFPIK3CDSYKGSK3B | |
| SCHEMBL10160905 | 0.84 | MAPKAPK5 (0.51) | MAPKAPK5SYKGSK3B | |
| SCHEMBL10160899 | 0.82 | MAPKAPK5 (0.67) | MAPKAPK5PIK3CD | |
| SCHEMBL10160937 | 0.79 | MAPKAPK5 (0.49) | MAPKAPK5GSK3BWNT1DYRK1APDE1B | |
| SCHEMBL10160896 | 0.79 | MAPKAPK5 (0.50) | MAPKAPK5PIK3CDSYKGSK3B | |
| SCHEMBL10160859 | 0.76 | MAPKAPK5 (0.51) | MAPKAPK5SYKGSK3B | |
| SCHEMBL10160830 | 0.75 | MAPKAPK5 (0.49) | MAPKAPK5PIK3CDSYKGSK3B | |
| SCHEMBL279907 | 0.72 | MAPKAPK5 (0.59) | MAPKAPK5GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006237-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-14 | — | — | US | disclosed |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | ANDREWS MARTIN JAMES INGLIS (BE) | 2012-09-13 | — | — | US | disclosed |
| US-8148369-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS, N.V. (BE) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012078-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | TNF, LITAF, CNKSR1 | MAPKAPK5 307/4885BRAF 475/4885PIK3CD 3995/4885 |
| US-20120232075-A1 | Fused Pyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases | TNF, LITAF, CNKSR1 | MAPKAPK5 307/4885BRAF 475/4885PIK3CD 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.